NCT03198026 2026-02-19
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Thomas Jefferson University
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT03479268 2025-11-26
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02207062 2025-01-07
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Completed
NCT04514393 2022-04-07
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Sun Yat-sen University
Phase 2 Unknown